Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)

F. Puig Sanchez (sevilla, Spain), L. Román Rodríguez (sevilla, Spain), M. Barca Hernando (sevilla, Spain), E. Márquez Martín (sevilla, Spain), B. Romero Romero (sevilla, Spain), J. Martín Juan (sevilla, Spain)

Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Session: Endobronchial ultrasound: from rookie to pro
Session type: E-poster session
Number: 2865
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Puig Sanchez (sevilla, Spain), L. Román Rodríguez (sevilla, Spain), M. Barca Hernando (sevilla, Spain), E. Márquez Martín (sevilla, Spain), B. Romero Romero (sevilla, Spain), J. Martín Juan (sevilla, Spain). Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC). 2865

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019

Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012


24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016

Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>
Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer
Year: 2021


Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer
Source: International Congress 2017 – Gene signatures in bronchial diseases
Year: 2017

Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011


Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center.
Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology
Year: 2019

Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010


How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015



Survivin expression in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010

Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020


XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012

Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009


p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007


Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002

The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009


MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002

Lung cancer
Source: Respipedia Article
Year: 2018